

# Tumours of Haematopoietic & Lymphoid Tissue Pathology Reporting Proforma



Mandatory questions (i.e. protocol standards) are in bold (e.g. **S1.01**).

## **S1.01 Identification**

Family name

Sex

Male

Female

Intersex/indeterminate

Given name(s)

Date of birth

DD - MM - YYYY

**G1.01 Patient identifiers**

e.g. MRN, IHI or NHI (please indicate which)

Date of request

DD - MM - YYYY

**G1.02 Accession number**

## **Clinical details**

### **S1.01 Identification and contact details of requesting doctor**

  
  

### **S1.01 Relevant clinical information** (per request form)

  
  

### **S1.02 Principal clinician**

### **S1.03 Site of biopsy**

Lymph node

Other

### **S1.04 Laterality**

Left

Midline

Right

Unknown

### **G1.03 Reason for biopsy**

  
  

### **G1.04 Clinical or differential diagnosis**

  
  

### **G1.05 Involved sites or pattern of disease spread**

Nodal/Lymphatic

Extranodal/Extralympathic

Nodal/Extranodal

Unknown

### **G1.06 Stage or clinical extent of disease**

Solitary

Localised

Generalised

Unknown

### **G1.07 Constitutional symptoms**

Present

Absent

Unknown

### **G1.08 Relevant laboratory test results**

G1.09 Previous lymphoma or leukaemia diagnosis

Relevant previous biopsies:

Date of biopsy

Site of biopsy

Type of biopsy

Laboratory

Lab reference nbr

G1.10 Previous treatment

G1.11 Predisposing factors—Immuno-compromised states and auto immune conditions

G1.12 Predisposing factors—Infective agents

G1.13 Further clinical information

### Macroscopic findings

**S2.01 Fluid in which specimen delivered to the laboratory**

**S2.02 Specimen handling or triage**

**S2.03 Specimen type**

**S2.04 Specimen size**

Biopsies  mm

Fluid  mL

Spleen  g

G2.03 Narrative or macroscopic description

### Microscopic findings

G3.01 Abnormal cells: patterns of infiltration or architecture

G3.02 Abnormal cell size

Small

Medium

Large

Mixed

Indeterminant

G3.03 Abnormal cell cytomorphology

G3.04 Abnormal cell proliferative indicators

**S3.02 Grade (follicular lymphoma)**

1

2

3

3a

3b

G3.05 Host cells and tissue reactions

G3.06 Narrative or microscopic description

### Ancillary test findings

#### Immunohistochemistry

**S4.01** Performed   
Not performed

#### S4.02

Positive Abs	
Negative Abs	
Equivocal Abs	

G4.05 Narrative interpretive comment

#### Flow cytometry studies

**S4.01** Performed   
Not performed

#### S4.02

Positive Abs	
Negative Abs	
Equivocal Abs	

G4.05 Narrative interpretive comment

#### Other tests 1

Test result type

Result

G4.05 Narrative interpretive comment

#### Other tests 2

Test result type

Result

G4.05 Narrative interpretive comment

### Synthesis and overview

#### S5.01 Lineage

G5.01 Clonality

#### S5.02 WHO disease subtype

G5.02 ICD-O-3 code

G5.03 Diagnostic summary

specimen type, tumour site and laterality, WHO diagnosis, grade where relevant

G5.04 Stage (AJCC/UICC 7th edition)\*\*

Stage I

Stage II

Stage III

Stage IV

#### S5.03 Overall case comment

Worksheet prepared by:

On:

DD - MM - YYYY

## TNM definitions

### AJCC/UICC staging for Hodgkin and non-Hodgkin lymphomas\*\*

#### Stage I

Involvement of a single lymphatic site (ie nodal region, Waldeyer's ring, thymus or spleen)(I),;or localised involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE)a,b Rare in Hodgkin lymphoma

#### Stage II

Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localised involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE) b,c The number of regions involved may be indicated by an Arabic numeral, as in, for example, II3.

#### Stage III

Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S)b,c,d Splenic involvement is designated by the letter S.

#### Stage IV

Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s). Stage IV includes any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.b,c,d

a Multifocal involvement of a single extralymphatic organ is classified as stage IE and not stage IV.

b For all stages, tumour bulk greater than 10 to 15 cm is an unfavourable prognostic factor.

c The number of lymph node regions involved may be indicated by a subscript: eg, II3. For stages II to IV, involvement of more than 2 sites is an unfavourable prognostic factor.

d For stages III to IV, a large mediastinal mass is an unfavourable prognostic factor.

Note: Direct spread of a lymphoma into adjacent tissues or organs does not influence classification of stage.

\*\*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).